R&D Briefing

CIRS RD Briefing 75 – Emergency Use Pathways (EUPs)

It has become clear that agencies have a number of pathways that can be used during public health emergencies for the authorisation of therapeutics and vaccines. Some of these [...]

2021-01-19T09:27:54+00:00May 6th, 2020|Tags: |

CIRS RD Briefing 74 – OpERA programme

CIRS has collected regulatory assessment data for over 20 years, initially with ICH and ICH-observing countries. The OpERA programme, “Optimising Efficiencies in Regulatory Agencies (OpERA)”, was initiated through CIRS [...]

2021-06-07T10:56:57+00:00January 8th, 2020|Tags: , |

CIRS RD Briefing 73 – HTA outcomes 2014-18

Timely recommendation for drug reimbursement by health technology assessment (HTA) agencies is critical to ensure that patient access to medicines of therapeutic value is not delayed. As part of an [...]

2025-03-20T16:47:21+00:00July 10th, 2019|Tags: , |

CIRS RD Briefing 71 – Trends in the regulatory landscape Latin America

To address the complex challenges in the global regulatory environment and the growing demand for patient access to new medicines, regulatory agencies in Latin America are actively engaging in regulatorystrengthening [...]

2021-01-19T11:05:26+00:00July 9th, 2019|Tags: , |

CIRS RD Briefing 72 – Trends in the regulatory landscape Asia

To address the complex challenges in the global regulatory environment and the growing demand for patient access to new medicines, regulatory agencies in Asia are actively engaging in regulatory-strengthening and [...]

2025-03-20T16:47:03+00:00July 9th, 2019|Tags: , |

CIRS RD Briefing 70 – New approvals in six regulatory authorities 2009-18

Major improvements in the regulatory environment as well as changes in strategies of multinational companies have led to a general decrease in the time to marketing authorisation and improved consistency [...]

2021-01-19T11:08:18+00:00May 13th, 2019|Tags: , |

CIRS RD Briefing 69: Review of HTA outcomes and timelines 2014-2017

Timely recommendation for drug reimbursement by health technology assessment (HTA) agencies is critical to ensure that patient access to medicines of therapeutic value is not delayed. As part of [...]

2021-01-22T11:58:11+00:00August 11th, 2018|Tags: |
Go to Top